Ablation of Ventricular Tachycardia: Who Is a Candidate and What to Expect?
Tuesday, April 5, 2:00-3:30 PM
While ablation for ventricular tachycardias (VT) has gained popularity, questions still remain as to who will best benefit from the procedure. Patient selection is key to optimizing success. The bar might be a bit lower when deciding who to ablate, but that doesn't negate the need to appropriately select patients.
Ablation in the setting of structural heart disease is more challenging than in the normal heart. Those with structural heart disease tend to have more reentrant circuits, as well as larger reentrant circuits deeper in the myocardium. Ablation of idiopathic VT in the normal heart presents fewer challenges.
Many of the hundreds of thousands of sudden cardiac deaths each year in the U.S. are caused by VTs that have converted into ventricular defibrillations. This underscores the need to treat VTs appropriately so they do not worsen.
This session acts as a primer on the role of ablation of VTs in various patient populations. As the medical field sees an increase in arrhythmia disorders, it is important for EPs to keep up to date on the best way to choose and treat patients.
Speaker Information
While ablation for ventricular tachycardias (VT) has gained popularity, questions still remain as to who will best benefit from the procedure. Patient selection is key to optimizing success. The bar might be a bit lower when deciding who to ablate, but that doesn't negate the need to appropriately select patients.
Ablation in the setting of structural heart disease is more challenging than in the normal heart. Those with structural heart disease tend to have more reentrant circuits, as well as larger reentrant circuits deeper in the myocardium. Ablation of idiopathic VT in the normal heart presents fewer challenges.
Many of the hundreds of thousands of sudden cardiac deaths each year in the U.S. are caused by VTs that have converted into ventricular defibrillations. This underscores the need to treat VTs appropriately so they do not worsen.
This session acts as a primer on the role of ablation of VTs in various patient populations. As the medical field sees an increase in arrhythmia disorders, it is important for EPs to keep up to date on the best way to choose and treat patients.
Speaker Information
- William G. Stevenson, MD, Brigham and Women's Hospital, Boston -- VT Ablation: Patient Selection and General Principles
- David Lin, MD, Hospital of the University of Pennsylvania, Philadelphia -- Ablation of VT in a Patient with a Structurally Normal Heart
- John L. Sapp, MD, Dalhousie University, Halifax, Nova Scotia -- Role of Ablation for VT in Patients with Structural Heart Disease
- Paul Khairy, MD, PhD, Montreal Heart Institute -- VT Ablation in Adults with Repaired Congenital Heart Disease
- Christian Wolpert, MD, Klinikum Ludwigsburg, Ludwigsburg, Germany -- Is VT Ablation Sufficient? Need for Concomitant Drug or Device Therapy